| Title |
Rituximab for Children with Immune Thrombocytopenia: A Systematic Review
|
|---|---|
| Published in |
PLOS ONE, May 2012
|
| DOI | 10.1371/journal.pone.0036698 |
| Pubmed ID | |
| Authors |
Yi Liang, Lingli Zhang, Ju Gao, Die Hu, Yuan Ai |
| Abstract |
Rituximab has been widely used off-label as a second line treatment for children with immune thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and interpret the available evidence, we conducted a systematic review to assess the efficacy and safety of rituximab for children with ITP. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| India | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 118 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 17% |
| Student > Master | 19 | 16% |
| Researcher | 17 | 14% |
| Other | 11 | 9% |
| Student > Ph. D. Student | 11 | 9% |
| Other | 25 | 21% |
| Unknown | 18 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 71 | 59% |
| Agricultural and Biological Sciences | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Business, Management and Accounting | 2 | 2% |
| Other | 8 | 7% |
| Unknown | 22 | 18% |